Gary William Middleton
Overview
Explore the profile of Gary William Middleton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer D, Jackson R, Springfeld C, Ghaneh P, Rawcliffe C, Halloran C, et al.
J Clin Oncol
. 2024 Dec;
:JCO2401118.
PMID: 39637340
Purpose: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival...
2.
Jones R, Psarelli E, Jackson R, Ghaneh P, Halloran C, Palmer D, et al.
JAMA Surg
. 2019 Sep;
154(11):1038-1048.
PMID: 31483448
Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with...
3.
Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C, et al.
Lancet
. 2017 Jan;
389(10073):1011-1024.
PMID: 28129987
Background: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic...